Role of Advanced Magnetic Resonance Imaging in Differentiating among Glioma Subtypes and Predicting Tumor-Proliferative Behavior

Abstract

Objective Gliomas are a devastating and heterogeneous group of primary brain tumors. Previously, the source of glioma was undetermined. Recent literature indicates that neural stem cells, or progenitors, are proposed to be the source of glioma. The prognosis of different types of gliomas differs due to their various biological tissue types. Besides the histological grade, the two useful immunohistochemistry markers that show the tumor's biological behavior are isocitrate dehydrogenase (IDH) labeling and the K_i-67 labeling index. We sought to determine the magnetic resonance imaging (MRI) characteristics associated with IDH mutational status and ascertain whether MRI combined with IDH mutational status, can better predict the clinical outcomes of gliomas.

Materials and Methods This period study was conducted in the Department of Radiology, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India for 5 years (May 2016–May 2021). The study cohort included 30 patients diagnosed with gliomas who underwent preoperative MRI followed by surgical resection and histopathological examination. Preoperative MRI images were done to assess qualitative tumor characteristics such as location, margin of tumor, extent, cortical involvement, cystic component, mineralization or hemorrhage, and contrast enhancement.

Discussion Differences in MRI features between IDH-mutant (MT) and IDH-wild-type (WT) groups were analyzed using the chi-square test for categorical variables and the Mann–Whitney U test for continuous variables. Statistical analysis was conducted using SPSS software.

Results Among the 30 patients evaluated, 18 had IDH-WT and 12 had IDH-MT type gliomas. Male predominance (73.33%) was noted in our study. Brainstem location, indistinct borders (83.33%), less cortical involvement (72.22%), less cystic changes (88.89%), more area of necrotic component (44.44%), significantly increased choline/creatine (Cho/Cr) ratio, and choline/N-acetyl aspartate (Cho/NAA) ratio favors IDH-WT tumors. Positive T2-fluid-attenuated inversion recovery mismatch sign is more frequently seen in IDH-MT (7/12; 58.33%) tumors than in IDH-WT (4/18; 22.22%) tumors. Whereas well-defined contours (66.67%), more cortical involvement (83.33%), more cystic changes (58.33%), and less area of necrotic component favor IDH-MT type tumors.

Conclusion MRI is a very promising and valuable tool for differentiating among glioma subtypes and predicting tumor-proliferative behavior in glioma cases. The combination of MRI characteristics with IDH mutation status enhances the predictive accuracy for clinical outcomes in glioma patients. This approach could potentially guide treatment planning and improve prognostic assessments.

Keywords

glioma - IDH mutational status - brain tumor - astrocytoma - glioblastoma

Authors' Contributions

G.G. did the major write up of this review article. Majority of the cases in this review article were diagnosed and followed up by G.G. and R.R. The work was carried under the guidance of R.R. and he provided us the insight and knowledge to diagnose indeterminate lesions with imaging alone. All the authors read the rough draft and provided valuable suggestions for the final draft. G.G. reviewed this article for corrections and final draft.

Publikationsverlauf

Artikel online veröffentlicht:
15. Oktober 2024

• References

• 1 Singh MS, Michael M. Role of xenobiotic metabolic enzymes in cancer epidemiology. Methods Mol Biol 2009; 472: 243-264
• 2 Buckner JC, Brown PD, O'Neill BP, Meyer FB, Wetmore CJ, Uhm JH. Central nervous system tumors. Mayo Clin Proc 2007; 82 (10) 1271-1286
• 3 Wen PY, Schiff D, Cloughesy TF. et al. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro-oncol 2011; 13 (04) 437-446
• 4 Louis DN, Perry A, Reifenberger G. et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016; 131 (06) 803-820
• 5 Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005; 64 (06) 479-489
• 6 Mandonnet E, Delattre J-Y, Tanguy M-L. et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol 2003; 53 (04) 524-528
• 7 Villanueva-Meyer JE, Wood MD, Choi BS. et al. MRI features and IDH mutational status of grade II diffuse gliomas: impact on diagnosis and prognosis. AJR Am J Roentgenol 2018; 210 (03) 621-628
• 8 Park YW, Han K, Ahn SS. et al. Prediction of IDH1-mutation and 1p/19q-codeletion status using preoperative MR imaging phenotypes in lower grade gliomas. AJNR Am J Neuroradiol 2018; 39 (01) 37-42
• 9 Ding H, Huang Y, Li Z. et al. Prediction of IDH status through MRI features and enlightened reflection on the delineation of target volume in low-grade gliomas. Technol Cancer Res Treat 2019; 18: 1533033819877167
• 10 Metellus P, Coulibaly B, Colin C. et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 2010; 120 (06) 719-729
• 11 Stummer W. Mechanisms of tumor-related brain edema. Neurosurg Focus 2007; 22 (05) E8
• 12 Yamashita K, Hiwatashi A, Togao O. et al. MR imaging-based analysis of glioblastoma multiforme: estimation of IDH1 mutation status. AJNR Am J Neuroradiol 2016; 37 (01) 58-65
• 13 Arevalo OJ, Valenzuela R, Esquenazi Y. et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a practical approach for gliomas, part 2. Isocitrate dehydrogenase status—imaging correlation. Neurographics 2017; 7 (05) 344-349
• 14 Deguchi S, Oishi T, Mitsuya K. et al. Clinicopathological analysis of T2-FLAIR mismatch sign in lower-grade gliomas. Sci Rep 2020; 10 (01) 10113-10125
• 15 Xu YJ, Cui Y, Li HX. et al. Noninvasive evaluation of radiation-enhanced glioma cells invasiveness by ultra-high-field (1)H-MRS in vitro. Magn Reson Imaging 2016; 34 (08) 1121-1127
• 16 Li X, Jin H, Lu Y, Oh J, Chang S, Nelson SJ. Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas. NMR Biomed 2004; 17 (01) 10-20
• 17 Narayana A, Chang J, Thakur S. et al. Use of MR spectroscopy and functional imaging in the treatment planning of gliomas. Br J Radiol 2007; 80 (953) 347-354
• 18 Chang J, Thakur S, Perera G. et al. Image-fusion of MR spectroscopic images for treatment planning of gliomas. Med Phys 2006; 33 (01) 32-40